CureMetrix - Version cmAngio - Investigational AI-Based Triage Software
cmAngio An investigational AI-based triage software that helps doctors assess a patient’s risk of coronary heart disease (CHD).
Software Details
cmAngio produces a CureMetrix Bradley ScoreTM based on the existence and characteristics of breast arterial calcifications in the mammogram. This proprietary score can then be used to help the care team assess the patient’s risk of CHD directly from their mammogram. The Bradley Score and their associated risk of CHD can be tracked over time to help patients and doctors understand their changing health profile.
Once validated, cmAngio can be used as a clinical decision support tool that will enable physicians and healthcare teams to:
- Identify women with a risk of coronary heart disease identified during routine breast cancer screening using mammography
- Enable clinical protocols that allow women at risk to be seen by their primary care physicians or cardiologists
- Help identify women who are at risk and might otherwise have gone undiagnosed until other more serious symptoms became apparent
Videos related to this software
-
Curemetrix Company Overview - Video
Leveraging the power of Artificial Intelligence (AI) CureMetrix is committed to advancing technology that improves disease detection and cancer survival rates across the globe. We believe that providing radiologists with the most advanced technology to support their evaluation of mammograms will support improved clinical and financial outcomes along with increased assurance for imaging centers, hospital systems and the patients they care for.
Customer reviews
No reviews were found for CureMetrix - Version cmAngio - Investigational AI-Based Triage Software. Be the first to review!